Compare SLRC & EVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SLRC | EVO |
|---|---|---|
| Founded | 2007 | 1993 |
| Country | United States | Germany |
| Employees | N/A | 4766 |
| Industry | Finance/Investors Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 803.0M | 821.2M |
| IPO Year | 2007 | N/A |
| Metric | SLRC | EVO |
|---|---|---|
| Price | $14.16 | $2.41 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 7 | 1 |
| Target Price | ★ $15.36 | $7.00 |
| AVG Volume (30 Days) | ★ 334.5K | 108.5K |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | ★ 11.45% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.70 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $1.09 | N/A |
| Revenue Next Year | N/A | $7.13 |
| P/E Ratio | $8.43 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $13.64 | $2.31 |
| 52 Week High | $17.26 | $4.80 |
| Indicator | SLRC | EVO |
|---|---|---|
| Relative Strength Index (RSI) | 41.52 | 28.78 |
| Support Level | $13.95 | $2.31 |
| Resistance Level | $15.52 | $3.78 |
| Average True Range (ATR) | 0.29 | 0.09 |
| MACD | -0.01 | -0.04 |
| Stochastic Oscillator | 32.98 | 9.98 |
SLR Investment Corp is a closed-end externally managed, non-diversified management investment company that has elected to be treated as a business development company. It provides U.S. middle market businesses and intermediaries with bespoke debt financing solutions to fund working capital, acquisition, refinancing and growth capital requirements. The company's investment objective is to generate both current income and capital appreciation through debt and equity investments. The company invests principally in leveraged middle-market companies in the form of senior secured loans, financing leases, and to a lesser extent, unsecured loans and equity securities.
Evotec is a drug discovery partnership firm providing solutions to pharmaceutical and biotechnology companies, academic institutions, foundations, and nonprofit organizations. The company offers services in a variety of therapeutic areas, including central nervous system disorders, diabetes, inflammation, oncology, infectious diseases, and women's health. The shared R&D segment, roughly 80% of sales, provides drug discovery and manufacturing services on a typical fee-for-service basis and integrated drug discovery collaborations based on its proprietary, internally developed assets. The Just-Evotec Biologics segment, about 20% of sales, offers CDMO services for biologics. As of 2023, the company has over 5,000 employees and 18 production sites mainly in Europe and the United States.